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Benefits of Neoadjuvant Radiotherapy
for Locally Advanced Rectal Cancer
Colorectal cancer is an important disease in Taiwan and
worldwide. From the data of the Cancer Registry of
Taiwan, its incidence and mortality have been among
the top 3 of all cancers for many years. Surgery is the
most important modality of treatment for both colon
and rectal cancer. However, local recurrence and/or
reduced quality of life due to loss of anal sphincter after
surgery for rectal cancer are not uncommon, especially
in locally advanced disease. Preoperative radiotherapy
(RT) with or without chemotherapy has been shown
to be effective in improving local control and resect-
ability for locally advanced disease,1,2 and provide 
a chance for sphincter preservation.3,4 Preoperative
radiation combined with chemotherapy may be more
helpful in local control than radiation alone.5 In most
parts of the world outside Europe, neoadjuvant RT 
is usually given in 1.8 Gy per fraction up to 45 Gy or
50.4 Gy for the pelvis over a period of 5 weeks or
longer (long course). Further boost may be given for
the gross disease. Surgery is often performed 4–6
weeks after RT.
In this issue of the journal, Twu et al6 reported
their experience utilizing preoperative concurrent che-
moradiotherapy (CCRT) for 46 patients with locally
advanced rectal cancer in Taichung Veterans General
Hospital. The chemotherapy consisted of 5-fluorouracil
(400 mg/m2) and leucovorin (20 mg/m2) given intra-
venously. Thirty-four of 43 patients (79%) receiving
curative surgery had a response. Thirty-two patients
(74%) received sphincter-saving surgery. Among those
who responded favorably to this combined treatment,
the local recurrence rate was low (6%) and R0 resection
rate high (97%). The acute toxicities related to CCRT
were mild and tolerable. Only 1 patient had grade III
or higher toxicity (neutropenia). These results are
similar to those from other phase II trials of neoadju-
vant chemoradiotherapy for rectal cancer.
Preoperative vs. Postoperative RT
For locally advanced rectal cancer, postoperative RT has
been used for decades to improve local control. The
advantage of postoperative RT lies in more accurate
pathologic staging of disease from the resected speci-
men. The drawbacks consist of relatively hypoxic tissue
after surgery, probable sphincter loss for lower-seated
tumors and large irradiated volumes after abdomino-
perineal resection. The benefits of preoperative RT
include better oxygenation of tumor before surgery,
less irradiated volume of small intestine and higher
chance of R0 resection for advanced disease, although
surgery is often delayed to several weeks after RT for
better downstaging effect. Overtreatment can occur
with this approach if clinical staging is not accurate.
There are a few prospective randomized trials com-
paring preoperative and postoperative RT for rectal
cancer. A German trial was the first phase III trial to
show the benefit of better local control with preoper-
ative than postoperative chemoradiotherapy, although
the survival rates in the 2 groups were similar.7 Patients
in the preoperative arm received RT of 50.4 Gy, while
patients in the postoperative arm received 55.8 Gy
(5.4 Gy boost was added). The chemotherapy regi-
men was the same for both arms, with continuous
infusion of 5-fluorouracil (1,000 mg/m2/d) for 5 days
during weeks 1 and 5. Grade 3 or 4 acute toxicities
occurred more frequently in the postoperative than
the preoperative group. Based on this evidence, pre-
operative CCRT has been used increasingly in the
management of this group of patients in recent years.
The treatment guidelines of the National Compre-
hensive Cancer Network of the United States also
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recommend preoperative chemoradiotherapy for stage
II or III rectal cancer.
Prognostic Factors
After curative surgery, tumor extension through the
rectal wall and spread to the regional lymph nodes are
the main criteria to estimate prognosis in rectal cancer
patients. The downstaging effects of chemoradiation—
as determined by a decrease of pathologic versus pre-
operative clinical T or N categories—have been used to
measure tumor response. However, preoperative stag-
ing techniques such as endorectal ultrasound (ERUS),
computed tomography (CT), or magnetic resonance
imaging (MRI), are limited in their ability to provide
accurate information on the T/N stages.8 Thus, assess-
ment of response comparing the preoperative ERUS
stage with the pathology stage may probably over- or
underestimate the tumor downstaging rate caused by
preoperative chemoradiation. An alternative method to
assess treatment response is achieved by grading his-
tologic changes in the resected specimen after preop-
erative treatment. Tumor regression grading (TRG)
was developed to assess the histologic response of
tumor after chemoradiation.9 Different TRG scoring
systems are used in different institutions. Good corre-
lation between TRG and survival were found in many
studies.10,11 That is, the more the tumor shrank, the
better the survival of patients. Therefore, pathologic
response assessed by TRG is perhaps a better prognos-
tic factor than downstaging for disease-free survival
after preoperative chemoradiotherapy.
Future Direction
With regard to the neoadjuvant chemotherapy regi-
men, concurrent 5-fluorouracil with/without folinate
combined with RT has been used for decades. In recent
years, UFT (a combination of tegafur and uracil) and
capecitabine have been shown to be safe to administer
concomitantly with radiation in rectal cancer.12,13 Other
early-phase clinical trials combining capecitabine with
oxaliplatin and radiation appear to be safe and demon-
strate promising efficacy. Current neoadjuvant rectal
trials have incorporated targeting agents, such as
cetuximab (Erbitux) and bevacizumab (Avastin), into
treatment regimens. To find the best chemoradiation
regimen for locally advanced rectal cancer, there is a
clear need for large-scale randomized phase III trials.
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